Results 41 to 50 of about 1,796 (202)

Blastic plasmacytoid dendritic cell neoplasm of the uterus [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2020
Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and very aggressive hematological malignancy derived from precursor of the plasmacytoid dendritic cell.
Đurđević Predrag, Todorović Željko, Jovanović Danijela, Čekerevac Ivan, Novković Ljiljana, Mitrović Slobodanka, Čemerikić Vesna, Otašević Vladimir, Antić Darko   +8 more
doaj   +1 more source

BPDCN: state of the art. [PDF]

Hematology Am Soc Hematol Educ Program
Abstract The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies is due to the growing understanding of its unique multiorgan clinical presentation and characteristic skin lesions. The occurrence of BPDCN is generally heralded by a multicompartmental
Pemmaraju N.
europepmc   +3 more sources

t(8;14)(q24;q32) in BPDCN [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019
Review on t(8;14)(q24;q32) in BPDCN, with data on ...
openaire   +2 more sources

Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature

eJHaem, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is recurrently mutated in epigenetic pathway genes. We studied the myeloid‐related genetic mutations in a cohort of five patients with BPDCN and one paired relapse case at our institution and ...
Xi Zhang, Eric D. Hsi, Genevieve M. Crane, Yu‐Wei Cheng   +3 more
doaj   +1 more source

Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Clinical Case Reports, 2021
BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.
Ken Sagou, Makoto Ito, Yuma Kawamura, Shun Ukai, Miyo Goto, Nobuaki Fukushima, Kazutaka Ozeki, Ryuichi Fukuyama, Akio Kohno   +8 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018
Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved.
openaire   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm : State of the art and prospects [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare tumour, which usually a_ects elderly males and presents in the skin with frequent involvement of the bone-marrow, peripheral blood and lymph nodes.
A. Calleri, A. Pileri, E. Derenzini, F. Melle, G. Motta, M.R. Sapienza, N. Pimpinelli, S. Fiori, S. Pileri, V. Tabanelli   +9 more
core   +1 more source

E-cadherin expression and blunted interferon response in blastic plasmacytoid dendritic cell neoplasm [PDF]

, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm derived from plasmacytoid dendritic cells (pDCs). In this study, we investigated by immunohistochemical analysis the expression of E-cadherin (EC) on pDCs in reactive lymph ...
Arisi, Mariachiara, Bernardelli, Andrea, Bugatti, Mattia, Cerroni, Lorenzo, Facchetti, Fabio, Giliani, Silvia Clara, Licini, Sara, Lonardi, Silvia, Lorenzi, Luisa, Tomaselli, Michela, Tucci, Alessandra, Vairo, Donatella, Vermi, William   +12 more
core   +2 more sources

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer

Case Reports in Hematology, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells.
Jiankun Tong, Sergei Aksenov, Beth M. Siegel, Lihong Wei, William H. Rodgers   +4 more
doaj   +1 more source

Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network [PDF]

, 2021
Background: Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an ...
Assaf, Chalid, Blazejak, Christoph, Gambichler, Thilo, Gosman, Janika, Klemke, Claus-Detlev, Nicolay, Jan P., Olk, Joanna, Stadler, Rudolf, Stendel, Sarja, Stranzenbach, Rene, Wehkamp, Ulrike, Weyermann, Maria, Wobser, Marion   +12 more
core   +1 more source